12 results on '"Trylesinski, Aldo"'
Search Results
2. WED-215 HeparDx™ (by Metadeq, Inc.) is a reliable biomarker-based non-invasive test for MASH, capable of detecting the presence of inflammation and ballooning.
- Author
-
Angelini, Giulia, Russo, Sara, Lembo, Erminia, Verrastro, Ornella, Guidone, Caterina, Liguori, Antonio, Harrison, Stephen A., Trylesinski, Aldo, Miele, Luca, and Mingrone, Geltrude
- Published
- 2024
- Full Text
- View/download PDF
3. Knowledge of liver fibrosis stage among adults with NAFLD/NASH improves adherence to lifestyle changes.
- Author
-
Carrieri, Patrizia, Mourad, Abbas, Marcellin, Fabienne, Trylesinski, Aldo, Calleja, José Luis, Protopopescu, Camelia, and Lazarus, Jeffrey V.
- Subjects
- *
HEPATIC fibrosis , *NON-alcoholic fatty liver disease , *MEDICAL personnel , *FATTY liver , *BODY mass index - Abstract
Background & Aims: Though lifestyle interventions can reverse disease progression in people with non‐alcoholic fatty liver disease/non‐alcoholic steatohepatitis (NAFLD/NASH), unawareness about disease severity might compromise behavioural changes. Data from this first international cross‐sectional survey of individuals with NAFLD/NASH were used to identify correlates of both unawareness about fibrosis stage and its association with adherence to lifestyle adjustments. Methods: Adults with NAFLD/NASH registered on the platform Carenity were invited to participate in an online 20‐min, six‐section survey in Canada, France, Germany, Italy, Spain and the United Kingdom to describe their experience with NAFLD/NASH and its care (N = 1411). Weighted binary and multinomial logistic regressions were performed to estimate the effect of explanatory variables on unawareness of fibrosis stage and poor adherence to lifestyle changes respectively. Results: In the study group, 15.5% had obesity and 59.2% did not know their fibrosis stage. After multiple adjustments, individuals with a body mass index (BMI) ≥35 were over twice as likely to not know their fibrosis stage. People with a BMI >30 had a threefold higher risk of having poor adherence to lifestyle changes. Unawareness about fibrosis stage was also significantly associated with poor adherence to lifestyle adjustments. Conclusions: As fibrosis stage is becoming the main predictor of NAFLD progression, improving patient–provider communication—especially for people with obesity—about liver fibrosis stage, its associated risks and how to mitigate them, is needed. Training for healthcare professionals and promoting patient educational programmes to support behaviour changes should also be included in the liver health agenda. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
4. Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events.
- Author
-
Boursier, Jerome, Hagström, Hannes, Ekstedt, Mattias, Moreau, Clemence, Bonacci, Martin, Cure, Sandrine, Ampuero, Javier, Nasr, Patrik, Tallab, Lilian, Canivet, Clémence M., Kechagias, Stergios, Sánchez, Yolanda, Dincuff, Eloise, Lucena, Ana, Roux, Marine, Riou, Jeremie, Trylesinski, Aldo, and Romero-Gomez, Manuel
- Subjects
- *
HEPATIC fibrosis , *NON-alcoholic fatty liver disease , *LIVER biopsy - Abstract
Previous studies on the prognostic significance of non-invasive liver fibrosis tests in non-alcoholic fatty liver disease (NAFLD) lack direct comparison to liver biopsy. We aimed to evaluate the prognostic accuracy of fibrosis-4 (FIB4) and vibration-controlled transient elastography (VCTE), compared to liver biopsy, for the prediction of liver-related events (LREs) in NAFLD. A total of 1,057 patients with NAFLD and baseline FIB4 and VCTE were included in a multicenter cohort. Of these patients, 594 also had a baseline liver biopsy. The main study outcome during follow-up was occurrence of LREs, a composite endpoint combining cirrhosis complications and/or hepatocellular carcinoma. Discriminative ability was evaluated using Harrell's C-index. FIB4 and VCTE showed good accuracy for the prediction of LREs, with Harrell's C-indexes >0.80 (0.817 [0.768-0.866] vs. 0.878 [0.835-0.921], respectively, p = 0.059). In the biopsy subgroup, Harrell's C-indexes of histological fibrosis staging and VCTE were not significantly different (0.932 [0.910-0.955] vs. 0.881 [0.832-0.931], respectively, p = 0.164), while both significantly outperformed FIB4 for the prediction of LREs. FIB4 and VCTE were independent predictors of LREs in the whole study cohort. The stepwise FIB4-VCTE algorithm accurately stratified the risk of LREs: compared to patients with "FIB4 <1.30", those with "FIB4 ≥1.30 then VCTE <8.0 kPa" had similar risk of LREs (adjusted hazard ratio [aHR] 1.3; 95% CI 0.3–6.8), whereas the risk of LREs significantly increased in patients with "FIB4 ≥1.30 then VCTE 8.0-12.0 kPa" (aHR 3.8; 95% CI 1.3–10.9), and even more for those with "FIB4 ≥1.30 then VCTE >12.0 kPa" (aHR 12.4; 95% CI 5.1–30.2). VCTE and FIB4 accurately stratify patients with NAFLD based on their risk of LREs. These non-invasive tests are alternatives to liver biopsy for the identification of patients in need of specialized management. The amount of fibrosis in the liver is closely associated with the risk of liver-related complications in non-alcoholic fatty liver disease (NAFLD). Liver biopsy currently remains the reference standard for the evaluation of fibrosis, but its application is limited by its invasiveness. Therefore, we evaluated the ability of non-invasive liver fibrosis tests to predict liver-related complications in NAFLD. Our results show that the blood test FIB4 and transient elastography stratify the risk of liver-related complications in NAFLD, and that transient elastography has similar prognostic accuracy as liver biopsy. These results support the use of non-invasive liver fibrosis tests instead of liver biopsy for the management of patients with NAFLD. [Display omitted] • At their published cut-offs, FIB4 and VCTE stratify patients with NAFLD into subgroups with significantly different prognoses. • Compared to liver biopsy in NAFLD, VCTE has similar accuracy for the prediction of liver-related events. • With regards to clinical events, the FIB4-VCTE stepwise algorithm accurately discriminates at-risk patients with NAFLD. • This algorithm should be used in the referral pathway to a liver specialist. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
5. Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study.
- Author
-
Rinella, Mary E., Dufour, Jean-Francois, Anstee, Quentin M., Goodman, Zachary, Younossi, Zobair, Harrison, Stephen A., Loomba, Rohit, Sanyal, Arun J., Bonacci, Martin, Trylesinski, Aldo, Natha, Macky, Shringarpure, Reshma, Granston, Tanya, Venugopal, Aditya, and Ratziu, Vlad
- Subjects
- *
FIBROSIS , *NON-alcoholic fatty liver disease , *ALANINE aminotransferase , *ASPARTATE aminotransferase , *LIVER biopsy , *ULTRASONIC imaging - Abstract
Non-alcoholic steatohepatitis (NASH) is a chronic, progressive fibrotic liver disease that can lead to cirrhosis. While liver biopsy is considered the reference standard for the histologic diagnosis of NASH and staging of fibrosis, its use in clinical practice is limited. Non-invasive tests (NITs) are increasingly being used to identify and stage liver fibrosis in patients with NASH, and several can assess liver-related outcomes. We report changes in various NITs in patients treated with obeticholic acid (OCA) or placebo in the phase III REGENERATE study. Patients with NASH and fibrosis stage F2 or F3 (n = 931) were randomized (1:1:1) to receive placebo, OCA 10 mg, or OCA 25 mg once daily. Various NITs based on clinical chemistry and/or imaging were evaluated at baseline and throughout the study. Rapid, sustained reductions from baseline in alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyltransferase levels, as well as in Fibrosis-4 (FIB-4), FibroTest, FibroMeter, and FibroScan-AST scores were observed in OCA-treated vs. placebo-treated patients. Reduction in liver stiffness by vibration-controlled transient elastography was observed in the OCA 25 mg group vs. the placebo group at Month 18. NIT changes were associated with shifts in histologic fibrosis stage. The greatest improvements were observed in patients with ≥1-stage fibrosis improvement; however, improvements in ALT, AST, FIB-4, and FibroTest were also observed in OCA-treated patients whose histologic fibrosis remained stable. Based on the REGENERATE Month 18 interim analysis, rapid and sustained improvements in various NITs were observed with OCA treatment. Dynamic changes in selected NITs separated histologic responders from non-responders. These results suggest that NITs may be useful in assessing histologic response to OCA therapy. NCT02548351 Non-alcoholic steatohepatitis (NASH) is a chronic, progressive liver disease that can lead to cirrhosis. To diagnose and assess liver fibrosis (scarring) in patients with NASH, non-invasive tests (NITs) are increasingly being used rather than liver biopsy, which is invasive, expensive, and can be risky. In the REGENERATE study, which is evaluating the effects of obeticholic acid vs. placebo in patients with NASH, various NITs were also evaluated. This analysis shows that improvements in levels of certain blood components, as well as favorable results of ultrasound imaging and proprietary tests of liver function, were associated with improvements in liver fibrosis after treatment with obeticholic acid, suggesting that NITs may be useful alternatives to liver biopsy in assessing NASH patients' response to therapy. [Display omitted] • Reduced ALT, AST, GGT, FIB-4, and FibroTest scores were seen with OCA vs. placebo. • Reduced liver stiffness by VCTE was observed in OCA vs. placebo arms at Month 18. • NIT changes in OCA treatment arms were associated with shifts in fibrosis stage. • The antifibrotic effect of OCA might be measurable with commonly used NITs. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
6. 52-Week Efficacy and Safety of Telbivudine with Conditional Tenofovir Intensification at Week 24 in HBeAg-Positive Chronic Hepatitis B.
- Author
-
Piratvisuth, Teerha, Komolmit, Piyawat, Tanwandee, Tawesak, Sukeepaisarnjaroen, Wattana, Chan, Henry L. Y., Pessôa, Mário G., Fassio, Eduardo, Ono, Suzane K., Bessone, Fernando, Daruich, Jorge, Zeuzem, Stefan, Cheinquer, Hugo, Pathan, Rashidkhan, Dong, Yuhong, and Trylesinski, Aldo
- Subjects
- *
HEPATITIS B treatment , *TENOFOVIR , *PHARMACODYNAMICS , *GLOMERULAR filtration rate , *CLINICAL pharmacology , *TREATMENT effectiveness , *CLINICAL trials - Abstract
Background and Aims: The Roadmap concept is a therapeutic framework in chronic hepatitis B for the intensification of nucleoside analogue monotherapy based on early virologic response. The efficacy and safety of this approach applied to telbivudine treatment has not been investigated. Methods: A multinational, phase IV, single-arm open-label study (ClinicalTrials.gov ID NCT00651209) was undertaken in HBeAg-positive, nucleoside-naive adult patients with chronic hepatitis B. Patients received telbivudine (600 mg once-daily) for 24 weeks, after which those with undetectable serum HBV DNA (<300 copies/mL) continued to receive telbivudine alone while those with detectable DNA received telbivudine plus tenofovir (300 mg once-daily). Outcomes were assessed at Week 52. Results: 105 patients commenced telbivudine monotherapy, of whom 100 were included in the efficacy analysis. Fifty-five (55%) had undetectable HBV DNA at Week 24 and continued telbivudine monotherapy; 45 (45%) received tenofovir intensification. At Week 52, the overall proportion of undetectable HBV DNA was 93% (93/100) by last-observation-carried-forward analysis (100% monotherapy group, 84% intensification group) and no virologic breakthroughs had occurred. ALT normalization occurred in 77% (87% monotherapy, 64% intensification), HBeAg clearance in 43% (65% monotherapy, 16% intensification), and HBeAg seroconversion in 39% (62% monotherapy, 11% intensification). Six patients had HBsAg clearance. Myalgia was more common in the monotherapy group (19% versus 7%). No decrease in the mean glomerular filtration rate occurred in either treatment group at Week 52. Conclusions: Telbivudine therapy with tenofovir intensification at Week 24, where indicated by the Roadmap strategy, appears effective and well tolerated for the treatment of chronic hepatitis B. Trial Registration: ClinicalTrials.gov NCT00651209 [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
7. Adefovir dipivoxil is effective for the treatment of cirrhotic patients with lamivudine failure.
- Author
-
Zoulim, Fabien, Parvaz, Parviz, Marcellin, Patrick, Zarski, Jean-Pierre, Beaugrand, Michel, Benhamou, Yves, Bailly, François, Maynard, Marianne, Trepo, Christian, Trylesinski, Aldo, and Monchecourt, Françoise
- Subjects
- *
MEDICAL research , *LIVER disease treatment , *HEPATITIS B , *ALANINE aminotransferase , *SERUM , *LIVER transplantation - Abstract
Background/Aims: Data on the efficacy of adefovir dipivoxil (ADV) in elderly and cirrhotic patients with lamivudine-resistant (LAM-R) chronic hepatitis B are scarce. This retrospective cohort study evaluated the safety and efficacy of ADV in this specific patient population. Methods: Sixty-eight cirrhotic LAM-R patients, of whom 19 (27.9%) were elderly (≥65 years of age) and nine had severe disease (two post-orthotopic liver transplantation, four pre-orthotopic liver transplantation and three decompensated), with hepatitis B virus (HBV) infection received ADV. Virological and biochemical responses to the addition of ADV were analysed. Results: At inclusion, all patients were receiving LAM; ADV was added. 75.4% of patients received a combination of LAM and ADV throughout this study for a median treatment duration of 12.6 months; the remainder received ADV with an overlap with LAM treatment for a median duration of 7.9 months. At the end of follow-up, 41.2% of patients had undetectable HBV DNA (≤2000 copies/ml) with a median reduction of 3.4 log10 copies/ml. Time to reach undetectable HBV DNA was dependent on baseline alanine aminotransferase (ALT) levels and HBeAg status. Normalization of serum ALT levels was observed in 55.2% (32/58) of patients. In patients who were HBeAg positive at baseline, HBeAg loss and seroconversion occurred in 23% (9/39) and 10% (4/39) respectively. No resistance mutations and no significant side effects were observed during the study period. Conclusion: Adefovir dipivoxil provides effective and safe treatment in cirrhotic and elderly patients who failed LAM therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
8. Comparative Selection of the K65R and M184V/I Mutations in Human Immunodeficiency Virus Type 1-Infected Patients Enrolled in a Trial of First-Line Triple-Nucleoside Analog Therapy (Tonus IMEA 021).
- Author
-
Delaunay, Christophe, Brun-Vézinet, Françoise, Landman, Roland, Collin, Gilles, Peytavin, Gilles, Trylesinski, Aldo, Flandre, Philippe, Miller, Michael, and Descamps, Diane
- Subjects
- *
HIV , *GENETIC mutation , *NUCLEOSIDES , *DISEASE management , *VIRUSES , *HIV-positive persons - Abstract
Tonus was a pilot study in which previously untreated human immunodeficiency virus type 1 (HIV-1)infected patients received the combination of abacavir, lamivudine, and tenofovir once a day. There was a high rate of early virological failure, and the M184V and K65R mutations were frequently detected at week 12 (W12). The objective of this study was to examine the selection dynamics of the K65R and M184V/I mutations. Bulk sequencing of the reverse transcriptase (RT) gene was performed on plasma HIV-1 RNA at baseline, W4, and W12 for 21 patients with detectable viral loads. The RT genes from baseline, W4, and W12 plasma samples from five patients who developed both M184V and K65R but with different mutational patterns were also cloned and screened for the K65R mutation by selective real-time PCR. At baseline, bulk sequencing and clonal analysis showed only wild-type RT sequences. At W4, M184V/I was detected in 12/19 patients and K65K/R in 2 patients by bulk sequencing. At W12, M184V/I was found in 18/20 patient, together with the K65R in 13 patients. At W4, clonal analysis revealed the K65R mutation in 0.6 to 48% of clones in the five patients studied. At W12, the K65R mutation was found in 30 to 100% of clones. K65R and M184V/I seemed to arise in separate clones, followed by an enrichment of viruses containing both mutations. The clinical relevance of this independent evolution is unclear. M184V/I was selected more frequently than K65R at W4. However, K65R was also detected early using a clone-sensitive genotyping method. All three nucleoside analogs are known to select the K65R and/or M184V/I mutation. This convergent genetic pathway to resistance, associated with lower antiretroviral potency, may explain the high selection rate of these mutations in this trial. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
9. FRI180 - Efficacy and tolerance of obeticholic acid in patients with primary biliary cholangitis and inadequate response to ursodeoxycholic acid in real life: interim analysis of the OCARELIFE study.
- Author
-
Vincent, Leroy, Corpechot, Christophe, Dumortier, Jérôme, Alric, Laurent, Larrey, Dominique, Dharancy, Sebastien, Chazouillères, Olivier, Heurgue-berlot, Alexandra, Boer, Francois, and Trylesinski, Aldo
- Subjects
- *
URSODEOXYCHOLIC acid , *CHOLANGITIS , *ACIDS , *LIVER diseases - Published
- 2020
- Full Text
- View/download PDF
10. THU048 - The burden of disease associated with non-alcoholic steatohepatitis patients under standard of care.
- Author
-
Pais, Raluca, Green, William, Mealing, Stuart, Trylesinski, Aldo, Cure, Sandrine, and Davies, Heather
- Subjects
- *
FATTY liver , *DISEASES , *PATIENT care - Published
- 2020
- Full Text
- View/download PDF
11. Effect of Highly Active Antiretroviral Therapy on Expression of Interleukin-10 and Interleukin-12 in HIV-Infected Patients.
- Author
-
Taoufik, Yassine, Peguillet, Isabelle, de Goer, Marie-Ghilaine, Lambert, Marion, Gubler, Brigitte, Trylesinski, Aldo, Delfraissy, Jean Francois, and Lantz, Olivier
- Subjects
- *
ANTIVIRAL agents , *INTERLEUKIN-10 , *INTERLEUKIN-12 , *HIV infections , *IMMUNOLOGY - Abstract
Presents information on a study which examined the effect of highly active antiretroviral therapy on expression of interleukin-10 and interleukin-12 in HIV-infected patients. Change in interleukin-12 production during HIV infection; Test procedures conducted on 12 patients; Results.
- Published
- 2001
- Full Text
- View/download PDF
12. A randomized trial of two-drug versus three-drug tenofovir-containing maintenance regimens in virologically controlled HIV-1 patients.
- Author
-
Girard, Pierre-Marie, Cabié, André, Michelet, Christian, Verdon, Renaud, Katlama, Christine, Mercié, Patrick, Morand-Joubert, Laurence, Pétour, Pascal, Monchecourt, Françoise, Chêne, Geneviève, and Trylesinski, Aldo
- Subjects
- *
ANTIRETROVIRAL agents , *MEDICAL virology , *HIV-positive persons , *VIRAL load , *MEDICAL centers , *CLINICAL trials , *MEDICAL protocols - Abstract
Objectives To assess simplified maintenance regimens containing dual antiretroviral drugs in patients with controlled human immunodeficiency virus type 1 infection. Methods A non-inferiority, randomized, multicentre, open-label trial was performed in 24 AIDS clinical centres in France randomizing 143 patients [treated for ≥6 months, plasma viral load (pVL) Results Success rates for the intention-to-treat analysis were 97.2% (70/72) versus 81.7% (58/71) in the three-drug versus two-drug maintenance regimen groups, respectively [difference, 15.5%; upper limit of one-sided 95% confidence interval (CI), 23.7%], and 100% (70/70) versus 90% (54/60) for the per protocol analysis, respectively (difference, 10%; upper limit of one-sided 95% CI, 16.4%), with a non-inferiority margin set at 14%. Three patients from the two-drug group experienced virological failure with selection of efavirenz-associated mutations. Overall, CD4 counts were significantly increased from baseline (median, +24 cells/mm3; P = 0.007). Four patients discontinued study treatment due to adverse events in the two-drug group and none in the three-drug group. No significant changes in creatinine clearance or phosphataemia were reported. Overall, levels of triglycerides, total and high-density lipoprotein cholesterol were improved; low-density lipoprotein cholesterol was improved only in the three-drug group. Conclusions The non-inferiority of the two-drug versus the three-drug regimen was not demonstrated. Lipid parameters improved after switching from twice-daily highly active antiretroviral therapy (HAART) to once-daily tenofovir-based HAART. [ABSTRACT FROM AUTHOR]
- Published
- 2009
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.